

## CLAIMS

1. An agent for treatment of metabolic bone disease, containing erythropoietin (EPO) as an active ingredient.
- 5 2. The agent for treatment according to claim 1, wherein said metabolic bone disease is renal failure-associated osteodystrophy, marble bone disease, diabetic nephropathy, or osteoporosis.
3. A method for treatment of metabolic bone disease,  
10 comprising administering erythropoietin to a patient with metabolic bone disease.
4. The method for treatment according to claim 2, comprising administering erythropoietin in a usual dose of 0.1 to 500 µg, preferably 5 to 100 µg, per adult.
- 15 5. The method for treatment according to claim 3, wherein said patient with metabolic bone disease is a patient with renal failure-associated osteodystrophy, marble bone disease, diabetic nephropathy, or osteoporosis.
6. A method for producing an agent for treatment of  
20 metabolic bone disease, comprising incorporating erythropoietin (EPO) as an active ingredient.
7. The method for producing an agent for treatment according to claim 7, wherein said metabolic bone disease is renal failure-associated osteodystrophy, marble bone  
25 disease, diabetic nephropathy, or osteoporosis.